Oncopeptides AB
STO:ONCO

Watchlist Manager
Oncopeptides AB Logo
Oncopeptides AB
STO:ONCO
Watchlist
Price: 4.805 SEK -3.22%
Market Cap: 1.2B SEK

Wall Street
Price Targets

ONCO Price Targets Summary
Oncopeptides AB

Wall Street analysts forecast ONCO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ONCO is 5.288 SEK with a low forecast of 5.236 SEK and a high forecast of 5.444 SEK.

Lowest
Price Target
5.236 SEK
9% Upside
Average
Price Target
5.288 SEK
10% Upside
Highest
Price Target
5.444 SEK
13% Upside
Oncopeptides AB Competitors:
Price Targets
6855
Ascentage Pharma Group International
95% Upside
4593
Healios KK
152% Upside
NTLA
Intellia Therapeutics Inc
144% Upside
688687
Beijing Kawin Technology Share-holding Co Ltd
94% Upside
EDIT
Editas Medicine Inc
147% Upside
206650
EuBiologics Co Ltd
71% Upside
MRNA
Moderna Inc
24% Upside
OCC
Orthocell Ltd
25% Upside

Revenue
Forecast

Revenue Estimate
Oncopeptides AB

The compound annual growth rate of Oncopeptides AB's revenue for the next 2 years is 186%.

N/A
Past Growth
186%
Estimated Growth
Estimates Accuracy
-23%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Oncopeptides AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Oncopeptides AB

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-56%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ONCO's stock price target?
Price Target
5.288 SEK

According to Wall Street analysts, the average 1-year price target for ONCO is 5.288 SEK with a low forecast of 5.236 SEK and a high forecast of 5.444 SEK.

What is Oncopeptides AB's Revenue forecast?
Projected CAGR
186%

The compound annual growth rate of Oncopeptides AB's revenue for the next 2 years is 186%.

Back to Top